Minaprine: Difference between revisions
CSV import |
CSV import |
||
| Line 18: | Line 18: | ||
[[Category:Monoamine oxidase inhibitors]] | [[Category:Monoamine oxidase inhibitors]] | ||
{{pharma-stub}} | {{pharma-stub}} | ||
<gallery> | |||
File:Minaprine.svg|Minaprine | |||
File:Minaprine synthesis 1989.svg|Minaprine synthesis 1989 | |||
</gallery> | |||
Revision as of 01:20, 20 February 2025
Minaprine is a reversible inhibitor of monoamine oxidase A (RIMA), a type of antidepressant, that was introduced in France in the 1970s for the treatment of depression.
Pharmacology
Minaprine acts as a reversible inhibitor of monoamine oxidase A (MAO-A), an enzyme that breaks down monoamines in the body. By inhibiting MAO-A, minaprine increases the levels of these monoamines, which include serotonin, norepinephrine, and dopamine. This increase in monoamines is thought to be responsible for the antidepressant effects of minaprine.
Clinical use
Minaprine was introduced in France in the 1970s for the treatment of depression. It has also been used to treat anxiety disorders, cognitive impairment, and fatigue. However, its use has declined in recent years due to the development of newer antidepressants with fewer side effects.
Side effects
The most common side effects of minaprine include nausea, dizziness, and insomnia. In rare cases, it can cause hypertensive crisis, a serious condition characterized by extremely high blood pressure.
See also
-
Minaprine
-
Minaprine synthesis 1989
